CELEX: 32021M10452
Language: en
Date: 2021-09-27 00:00:00
Title: Commission Decision of 27/09/2021 declaring a concentration to be compatible with the common market (Case No COMP/M.10452 - CPP INVESTMENTS / FOUNTAINVEST / LANGDI PHARMACEUTICAL) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

EUROPEAN COMMISSION
                                                                Brussels, 27.9.2021
                                                                C(2021) 7102 final
                                                                                 PUBLIC VERSION
                                                                Canada Pension Plan Investment
                                                                Board
                                                                One Queen Street East, Suite 2500
                                                                Toronto, ON M5C 2W5
                                                                Canada
                                                                FountainVest Capital Partners GP4
                                                                Ltd.
                                                                c/o Intertrust Corporate Services
                                                                (Cayman) Limited
                                                                One Nexus way, Camana Bay
                                                                Grand Cayman, KY1-9005
                                                                Cayman Islands
Subject:        Case M.10452 – CPP INVESTMENTS / FOUNTAINVEST / LANGDI
                PHARMACEUTICAL
                Commission decision pursuant to Article 6(1)(b) of Council Regulation
                                       1
                (EC) No 139/2004 and Article 57 of the Agreement on the European
                                    2
                Economic Area
Dear Sir or Madam,
1.      On 2 September 2021, the European Commission received notification of a proposed
        concentration pursuant to Article 4 of the Merger Regulation by which Canada
        Pension Plan Investment Board (“CPP Investments”, Canada) and FountainVest
        Capital Partners GP4 Ltd. (“FountainVest”, Cayman Islands) acquire within the
        meaning of Article 3(1)(b) of the Merger Regulation joint control of Beijing
        Zhendong Langdi Pharmaceutical Co., Ltd. and its subsidiaries (“Langdi
        Pharmaceutical”, China) by way of purchase of shares.3
1       OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’). With effect from 1 December 2009, the Treaty on
        the Functioning of the European Union (‘TFEU’) has introduced certain changes, such as the
        replacement of ‘Community’ by ‘Union’ and ‘common market’ by ‘internal market’. The terminology
        of the TFEU will be used throughout this decision.
2       OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).
3       Publication in the Official Journal of the European Union No C 365, 10.9.2021, p. 5.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.
 ---pagebreak--- 2. The business activities of the undertakings concerned are:
   −    CPP Investments is a professional investment management organisation that
        invests in public equities, private equities, real estate, infrastructure and fixed
        income instruments.
   −    FountainVest is an independent private equity firm. Sectors of focus include
        consumer, media & technology, healthcare, industrials, and financial services.
   −    Langdi Pharmaceutical is a pharmaceutical company mainly active in the
        production and supply of calcium supplements for children, pregnant and
        lactating women, menopausal women and elderly people, to help prevent and
        treat osteoporosis, which are registered as over-the-counter (OTC) products.
3. After examination of the notification, the European Commission has concluded that
   the notified operation falls within the scope of the Merger Regulation and of
   paragraph 5(a) of the Commission Notice on a simplified procedure for treatment of
   certain concentrations under Council Regulation (EC) No 139/2004.4
4. For the reasons set out in the Notice on a simplified procedure, the European
   Commission has decided not to oppose the notified operation and to declare it
   compatible with the internal market and with the EEA Agreement. This decision is
   adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of
   the EEA Agreement.
                                                    For the Commission
                                                    (Signed)
                                                    Olivier GUERSENT
                                                    Director-General
4  OJ C 366, 14.12.2013, p. 5.
                                                2